is mounjaro glp 1 drug Diabetes Patients Also Struggle to Access GLP-1 Agonists is mounjaro glp 1 drug
Description
Weight loss remains a central therapeutic driver: A reduction in body weight of at least 7 to 10 percent resolves NASH in approximately 65 to 90 percent of patients
GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure
Companies that make GLP-1 drugs urged patients to use the medications as intended
Gastroenterology 2007;132:21312157 [DOI] [PubMed] [Google Scholar] 2.DeFronzo RA
J Clin Invest (2014) 124(6):245663
Chen W, Wainer J, Ryoo SW, Qi X, Chang R, Li J, et al
